Mast Therapeutics Inc  

(Public, NYSEMKT:MSTX)   Watch this stock  
Find more results for NYSEAMEX:ANX
0.480
+0.028 (6.17%)
Aug 28 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.45 - 0.49
52 week 0.38 - 0.69
Open 0.46
Vol / Avg. 1.71M/842,570.00
Mkt cap 76.90M
P/E     -
Div/yield     -
EPS -0.24
Shares 163.61M
Beta 2.25
Inst. own 23%
Oct 29, 2015
Q3 2015 Mast Therapeutics Inc Earnings Release (Estimated) Add to calendar
Aug 13, 2015
Q2 2015 Mast Therapeutics Inc Earnings Call
Aug 12, 2015
Q2 2015 Mast Therapeutics Inc Earnings Release
Jun 11, 2015
Mast Therapeutics Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.15% -45.65%
Return on average equity -87.90% -53.92%
Employees 23 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 500
SAN DIEGO, CA 92130-3324
United States - Map
+1-858-5520866 (Phone)
+1-858-5520876 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Company's lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001's potential to treat patients with preserved ejection fraction (HFpEF).

Officers and directors

Brian M. Culley Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Brandi L. Roberts C.P.A Chief Financial Officer, Senior Vice President
Age: 41
Bio & Compensation  - Reuters
R. Martin Emanuele Ph.D Senior Vice President - Development
Age: 60
Bio & Compensation  - Reuters
Gregory D. Gorgas Senior Vice President - Commercial
Age: 52
Bio & Compensation  - Reuters
Edwin L. Parsley Chief Medical Officer & Senior Vice President
Age: 54
Bio & Compensation  - Reuters
Howard C. Dittrich M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
David A. Ramsay CPA Independent Director
Age: 50
Bio & Compensation  - Reuters
Lewis J. Shuster Independent Director
Age: 59
Bio & Compensation  - Reuters